HB 2116 Modifies methodology for reimbursing hospital costs

04/02/2017
HB 2116 VOTE: NO
In House Committe

Status (cverview) of bill:https://olis.leg.state.or.us/liz/2017R1/Measures/Overview/HB2116
Committee assigned to bill:https://olis.leg.state.or.us/liz/2017R1/Committees/HHC/Overview

Published on Track Their Vote 


This bill helps Big Pharma peddle drugs to persons facing high drug bills. No incentive to lower costs; in fact, the opposite. Contains blanks for moneys needed; blank checks. Dangerous definition of 'person' who may benefit includes insurers and others.

Personal Choice and Responsibility
A popular bill in that it will supposedly aid 'persons' but in the long run, will encourage higher costs and no incentive to 'persons' or pharmaceutical companies to reign in costs.

Fiscal Responsibility
This bill could mushroom and be terribly expensive to the state, as there is no indication what an 'unusual' drug is, nor of probable costs, nor of personal responsibility. HB 2116 simply opens the Treasury to undetermined amounts as the directors see fit.

Limited Government
No limits on the spending allowed in HB 2116. No sundown, no responsibilities of any of the beneficiaries, no limits in any way.

Local Control
Citizens have no input. Directors determine amount to be spent/disbursed. Qualifying amounts undefined, left open to future manipulation.

Free Markets
Will distort markets with a flood of money into certain 'unusual' drug costs with no responsibility.

Leave a Reply

Time limit is exhausted. Please reload the CAPTCHA.